

Table DS1 Primary study outcomes: bed use and substance use (analyses presented are mean differences for quantitative outcomes and odds ratios for binary outcomes)

	Experimental group ¹	Control group ²	Unadjusted analysis (95% CI)	P	Analysis adjusted for baseline (95% CI)	P
Quantitative outcomes: mean (s.d.)						
Time in hospital in 18 months, days	74.9 (142.6)	71.8 (128.1)				
Log(days in hospital in 18 months+1)	2.0 (2.4)	2.1 (2.4)	−0.17 (−0.92 to 0.48) ³	0.6	−0.32 (−0.93 to 0.29) ³	0.30
Total substance use in month before follow-up interview ⁴						
Total alcohol use, standard units	104.7 (169.4)	130.4 (223.2)	−0.26 (−0.74 to 0.21) ³	0.25	0.21 (−0.66 to 1.08) ³	0.61
Total cannabis use, £ ⁵	35.11 (70.26)	32.71 (98.07)	−0.02 (−0.71 to 0.67) ³	0.95	0.26 (−0.44 to 0.96) ³	0.44
Total other drug use, £ ⁵	33.36 (154.38)	124.79 (470.22)	−0.31 (−1.03 to 0.41) ³	0.37	0.00 (−0.72 to 0.73) ³	0.99
Binary outcomes, n (%)						
Admitted in follow-up period	49 (43)	47 (48)	0.82 (0.50 to 1.34) ⁶	0.42	0.68 (0.39 to 1.19) ⁶	0.18
Any alcohol use in month before follow-up interview	56 (74)	54 (71)	1.14 (0.61 to 2.12) ⁶	0.68	1.76 (0.64 to 4.85) ⁶	0.27
Any cannabis use in month before follow-up interview	24 (32)	27 (36)	0.84 (0.42 to 1.68) ⁶	0.62	1.14 (0.46 to 2.85) ⁶	0.78
Any other drug use in month before follow-up interview	12 (16)	13 (18)	0.92 (0.42 to 2.02) ⁶	0.84	1.14 (0.38 to 3.44) ⁶	0.78

1. Experimental group $n=127$ at baseline (81 interviewed), $n=113$ at follow-up (76 interviewed).

2. Control group $n=105$ at baseline (78 interviewed), $n=97$ at follow-up (76 interviewed).

3. Mean difference between experimental and control group.

4. All figures for consumption were logarithmically transformed prior to analysis because all were substantially skewed.

5. For cannabis and other drugs, data were collected using the Maudsley Addiction Profile on amounts consumed and converted to a total monetary value based on current street values of each drug in south London at the time of the study, as estimated by a local organisation providing drug services.

6. Experimental–control group odds ratio.